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Hepatocytes are the primary targets of the hepatitis C virus
(HCV). While immunosuppressive roles of HCV core protein
have been found in several studies, it remains uncertain
whether core protein expressed in hepatocytes rather than in
immune cells affects the CD8
+ T cell response. In order to
transduce genes selectively into hepatocytes, we developed a
baculoviral vector system that enabled primary hepatocytes to
express a target epitope for CD8
+ T cells, derived from
ovalbumin (OVA), with or without HCV core protein. Culture
of OVA-specific CD8
+ T cells with hepatocytes infected with
these baculoviral vectors revealed that core protein has no
effect on proliferation or apoptosis of CD8
+ T cells. Our results
suggest that HCV core protein does not exert its suppressive
role on the CD8
+ T cell immune response through expression
in hepatocytes.
Key Words: Hepacivirus, T cells, cytotoxic, viral core pro-
teins, baculoviridae, co-culture techniques
INTRODUCTION
The hepatitis C virus causes chronic hepatitis in
more than 50% of infected patients.
1 One of the
mechanisms proposed to explain chronic HCV
infection is a weak immune response to HCV,
especially the response exerted by CD8
+ cytotoxic
T lymphocytes (CTL), as the CTL response in
HCV infection was found to be weaker and shor-
ter lived in chronically-infected human patients
than in individuals who resolved the HCV infec-
tion.
2,3 Moreover, in the chimpanzee, the only
animal model for HCV infection, the animals with
strong CTL responses were most likely to resolve
the infection.
4
Not surprisingly, the mechanisms through
which HCV may evade the immune response are
of great interest. To date, studies have shown the
virus to be highly mutable and capable of gene-
rating frequent escape mutations.
5,6 HCV proteins
may even exert a direct immunosuppressive
effect, although data on this point are contradic-
tory. HCV core protein was reported to suppress
the CD8
+ T cell response in a mouse model using
a vaccinia viral vector.
7 Later, the same research
group showed that interaction between HCV core
protein in the blood and the complement receptor
specific for the globular heads of the complement
C1q protein, gC1qR, inhibited production of IL-12
by human monocyte/macrophages and prolifera-
tion of human T cells.
8-10 Finally, circulating HCV
core protein inhibited effector cytotoxic T cell
differentiation.
11
In line with the above results, T cells from
transgenic mice that expressed the core gene
under control of the CD2 promoter showed de-
creased production of IFN- and IL-2. γ
12 In con-
trast, induced expression of HCV core protein in
the liver using an adenovirus vector did not affect
priming of CTL, cytokine production, infiltration
of lymphocytes into the liver, or liver injury.
13 In
support of these negative findings, mice were able
to clear infections of recombinant adenoviruses
that did or did not express HCV core and enve-
lope proteins.
14 Due to the apparent contradic-
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tions in these data, it is uncertain whether HCV
core protein expressed in the hepatocyte, the
major site of HCV replication, can regulate the
CTL response.
With the intent of clarifying some of the issues
surrounding HCV infection and immune re-
sponse, we developed a baculoviral vector ex-
pressing the Enhanced Green Fluorescent Protein
(EGFP) and ovalbumin (OVA) peptide for CD8
+ T
cell recognition, with or without the HCV core
protein. The baculoviral vector was chosen for its
efficiency in delivering genes to primary hepato-
cytes and for its hepatocyte tropism.
15,16 Our
vector system also has the advantage that the
antigenic epitope recognized by CD8
+ T cells is
distinct from the HCV protein under investigation
because the epitope is engineered into the marker
of target cell infection, EGFP. Using this vector
system and a co-culture model in which primary
mouse hepatocytes stimulate OVA peptide-speci-
fic CD8
+ T cells, we found that HCV core protein
expressed in primary hepatocytes did not modu-
late either the proliferation or apoptosis of anti-
gen-specific CD8
+ T cells.
MATERIALS AND METHODS
Construction of baculoviral vectors
To facilitate detection of infected hepatocytes,
we constructed baculoviral vectors expressing
EGFP. The fragment of pIRES-EGFP (Clontech)
between the NsiI and SspI recognition sites, which
contains the EGFP-coding gene sequence under
the IRES sequence controlled by the CMV pro-
moter, was inserted between the PstI and StuI
sites of pAcSG2 (BD PharMingen). Oligonucleo-
tides coding for ovalbumin amino acids 250
through 264 were ligated to the end of the EGFP
coding gene sequence using the BsrG1 and NotI
sites. The ligation was confirmed by resequencing.
The NsiI/SspI fragment of pIRES-EGFP-OVA was
then transferred to pAcSG2. The HCV core gene
was amplified using HCV 1a cDNA as template
(Dr. C. M. Rice, The Rockefeller University) and
sense and anti-sense primers containing the NheI
and BamHI sites, respectively; 5'-GCCTAGCTA
GCATGAGCACGAATCCTAAACCTC-3';
5'-CGGGATCCTTAGGCTGAAGCGGGCACA-3'.
The PCR product was introduced into the
pAcSG2-EGFP-OVA vector downstream of the
CMV promoter (Fig. 1A). Successful construction
of the vector was verified by sequencing.
Production and titration of recombinant baculo-
viruses
Recombinant baculoviruses were produced by
cotransfecting Sf9 cells with baculoviral Gold
DNA (BD PharMingen) and the baculoviral trans-
fer vectors (pAcSG2-EGFP, pAcSG2-EGFP-OVA,
and pAcSG2-Core-EGFP-OVA). Recombinant
baculoviruses were amplified in Sf9 cells and
concentrated by centrifugation of the culture
supernatant at 6000 rpm for 16 h at 4 . The virus
pellet was resuspended in DMEM-F12 media
(GibcoBRL). To determine the amount of baculo-
virus for hepatocyte infection, a serial dilution of
baculoviruses was added to CHO cells (2 × 10
4)
and the percentage of infected cells showing green
fluorescence analyzed by flow cytometry.
Infection of primary hepatocytes with baculo-
virus
The livers of C57BL/6 (B6) mice were perfused
via the portal vein with liver perfusion medium
(GibcoBRL) and liver digestion medium (Gibco
BRL). The released hepatocytes were washed
twice by centrifugation at 50 g in order to deplete
endothelial and Kupffer cells. Dead cells were
removed by Percoll gradient centrifugation. After
washing, 2 × 10
4 hepatocytes were added to each
well of 48-well plates (Falcon) and allowed to
adhere overnight before being infected with
baculovirus vector. The virus was titrated based
on its ability to infect CHO cells, and each well
was given ten times the amount required for 50%
infection of 2 × 10
4 CHO cells. To visualize the
selective infection of hepatocytes with baculo-
virus, liver cells were prepared as above except
with omission of the low speed centrifugation
step, allowed to adhere overnight, infected for 24
h with baculovirus expressing EGFP, and labeled
with acetylated low-density lipoprotein conju-
gated to DiI (DiI AcLDL, Molecular Probes) for
the final 16 h. DiI AcLDL labels Kupffer andEffect of Hepatitis C Virus Core Protein on CD8
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endothelial cells but not hepatocytes.
17,18 The cells
were photographed using an Olympus fluorescent
tissue culture microscope with digital image cap-
ture.
OVA peptide presentation by hepatocytes
Baculovirus-infected hepatocytes were stained
on ice for 1 h using 25-D1. 16 hybridoma cell
culture supernatant containing antibodies specific
to the molecular complex of H-2K
b and SIINFEKL
OVA peptide (Dr. R. Germain, National Institutes
of Health).
19 After washing, cells were incubated
with PE-conjugated anti-mouse Ig sera on ice for
30 min, followed by fixation with 2% parafor-
maldehyde and visualization with a fluorescence
microscope.
Baculovirus-infected hepatocytes (2 × 10
4 cells/
well) were co-cultured with a T cell line originally
derived from OT-1 mice (2 × 10
5 cells/well) that
had been left untreated for 8 days before the start
of co-culture. TCR of this T cell line is specific to
the complex of H-2K
b and SIINFEKL OVA
peptide. After 2 days, the culture supernatant was
harvested and interferon- production measured γ
using an ELISA kit (Endogen).
RT-PCR and Western blot
Total RNA of hepatocytes after 24 h of bacu-
loviral infection was isolated using an RNA
isolation kit (BD PharMingen). To remove conta-
minated vector DNA, the RNA samples were
treated with DNase I (1U/ l, Invitrogen) for 15 μ
Fig. 1. Baculovirus-mediated gene expression in hepatocytes. (A) Schematic representation of a baculoviral vector
expressing HCV core and EGFP-OVA. (B) Primary mouse hepatocytes were observed after 24 h of infection with baculo-
virus expressing EGFP. (C) Liver cells infected with baculovirus expressing EGFP were incubated with DiI AcLDL (red)
for the final 16 hours. Images from a fluorescence tissue culture microscope were merged using Adobe PhotoShop. (D)
Hepatocytes infected with baculovirus expressing EGFP alone or EGFP-OVA were stained with Ab specific to the
H-2K
b-OVA peptide complex and PE-conjugated secondary Ab (lower panels). (E) PCR was performed using DNase-
treated total RNA or cDNA prepared from hepatocytes infected with baculovirus expressing HCV core protein. (F) Extracts
of baculovirus-infected hepatocytes were subjected to SDS-PAGE, and HCV core protein was detected by immunoblotting
with a specific rabbit antiserum. HCV, hepatitis C virus; EGFP-OVA, enhanced green fluorescent protein-ovalbumin.
(A) (B) (C)
(D)
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min at room temperature and then reverse tran-
scribed using oligo-dT primers. With cDNA or
RNA as a template and the core primer set, PCR
was performed using an MJ Research thermal
cycler.
Hepatocytes after 24 h of infection were lysed
in RIPA buffer [50-mM TrisCl, pH 7.5, 150-mM
NaCl, 1-mM EGTA, 0.5% Nonidet P-40, 0.5%
deoxycholate, 1-mM 4-(2-aminoethyl)-benzenesul-
fonyl fluoride, 0.3- M aprotinin, and 1- M leu μ μ -
peptin]. Proteins were separated by 15% SDS-
PAGE, transferred to polyvinylidene difluoride
membranes, and visualized by Western blot an-
alysis using rabbit sera specific to HCV core
protein (Dr. Y. C. Sung, Pohang University of
Science and Technology, Korea) and the enhanced
chemiluminescent system (Amersham Pharmacia
Biotech).
Purification of CD8
+ T cells
Lymph nodes and spleen cells were isolated
from OT-1 transgenic mice
20 originally provided
by Dr. Francis Carbone (University of Melbourne,
Australia). These B6 mice expressed TCR specific
to the SIINFEKL OVA peptide bound to H-2K
b, to
which the CD45.1 marker had been back-crossed.
CD8
+ T cells were purified using magnetic beads.
Briefly, cells were incubated with beads coupled
to anti-mouse IgM (Polysciences, Inc., PA) for 30
min on ice, and then those cells attached to the
beads were removed with a magnet. Cells were
incubated for 30 min at 4 with a mixture of
antibodies against mouse CD4 (GK1.5), NK1.1
(HB-191), Fc R (2-4G2), and MHC class II mole γ -
cule (212.A1). After one washing, cells were resus-
pended in HBSS containing 5% FBS and magnetic
beads conjugated to anti-mouse IgG Ab, anti-rat
IgG Ab, and anti-mouse IgM Ab. Non-attached
cells were harvested. Flow cytometry indicated
that the purity of the CD8
+ T cells was between
90 and 98%.
Co-culture of primary hepatocytes with OT-1 T
cells
To quantitate apoptosis, purified OT-1 CD8
+ T
cells (2 × 10
5 cells/well) were added to hepatocyte
cultures, and the terminal deoxynucleotidyl-
transferase-mediated dUTP-biotin nick end-la-
beling (TUNEL) assay was conducted according to
the manufacturer's instructions (Roche Applied
Science). For the proliferation assay, purified OT-1
T cells (2 × 10
5 cells/well), labeled with 5,6-car-
boxy-fluorescein diacetate succinimidyl ester
(CFSE; Molecular Probe) by incubation of 1 × 10
7
cells in PBS containing 1- M CFSE at 37 for 10 μ
min, were added to hepatocyte cultures. After
co-culture, OT-1 T cells were harvested in PBS
containing 10-mM EDTA, washed, and stained
with antibodies raised against CD8 and CD45.1
(BD PharMingen). Flow cytometry analysis was
performed using CELLQuest
TM (Becton Dickin-
son).
RESULTS
Baculovirus-mediated gene expression in
hepatocytes
For easy detection of baculovirus-infected hepa-
tocytes, the eukaryotic gene expression cassette
for EGFP was introduced into the baculoviral
vector. As shown in Fig. 1B, EGFP was expressed
by infected hepatocytes. Preferential infection of
hepatocytes with baculovirus was demonstrated
by labeling of endothelial cells and Kupffer cells
with DiI AcLDL (Fig. 1C). Although liver cells
were prepared without the usual depletion of
non-parenchymal cells, only a few cells were
found to be labeled with DiI AcLDL after 40 h in
culture. Cells expressing EGFP were large and
double nucleated, as is characteristic of hepato-
cytes, and did not overlap with DiI AcLDL- la-
beled cells.
We examined OVA peptide presentation by
hepatocytes infected with baculovirus using an
antibody specific for the molecular complex of H-
2K
b and OVA peptide. This Ab stained the cyto-
plasmic membranes of hepatocytes expressing the
EGFP-OVA peptide fusion protein (EGFP- OVA)
but not those expressing EGFP alone (Fig. 1D,
lower panel). The molecular complex of H-2K
b
and OVA peptide on hepatocytes was also
recognized by a T cell line derived from OT-1
mice, leading to interferon- production (Table 1). γ
We confirmed expression of HCV core proteinEffect of Hepatitis C Virus Core Protein on CD8
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using RT-PCR and Western blotting (Fig. 1E and
F). The RT-PCR product was approximately 600
bp, and the protein 22 kDa, in line with expec-
tations for HCV core RNA and protein. A control
PCR reaction from which the reverse transcription
step was omitted gave no product, showing that
the RT-PCR product was not amplified from
contaminating vector DNA.
Effect of HCV core protein on proliferation of
Ag-specific CD8
+ T cells
To compare proliferation of CD8
+ T cells in the
cultures expressing EGFP-OVA with and without
co-expression of HCV core protein, it was neces-
sary to standardize the frequency of hepatocyte
infection. This was done by titrating the recom-
binant viruses using flow cytometry to detect
EGFP expression in CHO cells, which are infec-
tible cells like hepatocytes (data not shown). This
method is simple and rapid (requiring only 2
days), as compared to the plaque forming unit as-
say (7 to 10 days). With our flow cytometry
method, we were able to obtain similar levels of
hepatocyte infection with baculoviruses express-
ing EGFP alone, EGFP-OVA, and HCV core-
EGFP-OVA (Fig. 2A).
Proliferation of OT-1 CD8
+ T cells was visual-
ized by monitoring CFSE dilution after co-culture.
Proliferation was not observed at 24 h of co-
culture, except in the positive control wells pulsed
with OVA peptide (data not shown). On the
second day of co-culture, the most divisions were
seen in T cells responding to hepatocytes pulsed
with OVA (Fig. 2B). Control experiments with
hepatocytes lacking expression of OVA peptide
(expression of EGFP alone or uninfected) indi-
cated that proliferation of OT-1 T cells was anti-
gen specific: OT-1 T cells proliferated in response
to hepatocytes expressing EGFP-OVA, while co-
expression of HCV core protein did not result in
either more or less frequent divisions than did
expression of EGFP-OVA alone (Fig. 2). Experi-
ments with less baculovirus similarly showed no
difference between EGFP-OVA and HCV core-
EGFP-OVA (data not shown).
Effect of HCV core protein on apoptosis of Ag
specific CD8
+ T cells
In chronic hepatitis C patients, apoptosis of T
cells in the peripheral blood and liver has been
reported to be higher than in normal volunteers.
21,22
The proper interpretation of this finding is un-
clear, however, because after antigenic stimula-
tion, apoptosis of T cells is increased.
23,24 We in-
vestigated the apoptosis of CD8
+ T cells stimu-
lated with hepatocytes expressing OVA alone or
OVA with HCV core protein. Analysis 60 h after
co-culture indicated that expression of HCV core
protein did not affect T cell apoptosis (Fig. 3).
Similarly, experiments with a lower amount of
baculovirus showed no effect of HCV core protein
on T cell apoptosis (data not shown). Finally, we
conducted experiments with previously activated
T cells, and, like naive cells, these showed no dif-
ferences in apoptosis when the vector contained
the HCV core or EGFP-OVA alone (data not
shown). Likewise, the secretion of interferon-γ
was no different when T cells responded to the
vector containing HCV core (data not shown).
DISCUSSION
Our results help to resolve apparent contradic-
tions in the literature concerning the immuno-
suppressive effects of HCV core protein. We
Table 1. IFN- Production by an OT-1 T Cell Line Stimulated with Baculovirus-Infected Hepatocytes γ
MOI. GFP expression GFP-OVA expression
10 0.146 0.275
100 0.073 0.688
Data represent O.D.
IFN- production by an OT-1 T cell line co-cultured with baculovirus-infected hepatocytes was measured by ELISA over 2 days. γ
O.D. of culture with uninfected hepatocytes was 0.127. Similar data were obtained in 6 experiments using OT-1 CD8
+ T cells purified
from naïve mice; MOI, multiplicity of infection; GFP, green fluorescent protein; OVA, ovalbumin.Young-Hee Jin, et al.
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found that HCV core protein expressed in hepato-
cytes does not affect T cell activation, which
agrees with a separate study using an adenovirus
vector.
13 Different conclusions were drawn,
however, from experiments in which expression
of HCV core protein, as mediated by vaccinia
virus, suppressed a CTL immune response in
mice.
7 These contradictory findings may be due to
differences between the adenoviral and vaccinia
viral vectors in terms of hepatocyte tropism and
infection of immune cells.
We propose that HCV core protein does not
alter T cell function when expressed in hepato-
cytes, but rather, does so when expressed in
leukocytes, including T cells. This position is
supported by the observation that T cells express-
ing HCV core protein produced low amounts of
cytokines, including IL-2, and showed increased
sensitivity to Fas-mediated apoptosis.
12,25,26 The
role of HCV core protein in myeloid lineage cells
is supported by the finding that human dendritic
cells transduced with an adenovirus coding for
HCV core and E1 proteins were poor stimulators
for proliferation of allogeneic and autologous T
cells.
27 In addition, the proliferation of T cells and
Fig. 2. HCV core protein does not affect proliferation of
CD8
+ T cells. (A) Comparable levels of infection were
demonstrated after 24 h of hepatocyte infection with
baculoviruses expressing EGFP alone, EGFP-OVA, and
HCV core-EGFP-OVA. (B) CFSE-labeled OT-1 CD8
+ T
cells were co-cultured with hepatocytes infected with
baculovirus or pulsed with OVA peptide. Two days
later, T cells were collected and analyzed by FACS.
CFSE histograms of OT-1 T cells are gated on CD45.1
+
CD8
+ cells. Data represent three separate experiments.
Fig. 3. HCV core protein does not affect apoptosis of
CD8
+ T cells. OT-1 CD8
+ T cells were added to hepato-
cyte cultures expressing EGFP-OVA with or without HCV
core protein. CD8
+ T cells were collected, stained, and
analyzed by FACS 60 h after co-culture. TUNEL histo-
grams of OT-1 T cells are gated on CD45.1
+ CD8
+ cells.
Data represent three separate experiments.
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IFN- production in mixed lymphocyte reactions γ
with HCV core-expressing macrophages were
inhibited.
28
Rigorous analysis of T cell biology during HCV
infection in vivo is difficult because chimpanzee is
the only animal model of HCV infection. In liver
and blood samples derived from chronic hepatitis
C patients, apoptosis of T cells has been reported
to be increased in comparison with normal sam-
ples.
21,22 Also, mitogen-activated monocytes from
chronic hepatitis C patients induced CD4
+ and
CD8
+ T cell apoptosis in a co-culture system.
29
These studies appear to support the animal and
in vitro experiments suggesting that HCV is im-
munosuppressive through induction of T cell
apoptosis.
CD8
+ T cell apoptosis has been proposed to
occur preferentially in the liver,
30 and, although
bone marrow-derived cells seem to be the main
players in intrahepatic CD8
+ T cell apoptosis, Ag
expression in liver parenchymal cells is important
for promoting the intrahepatic trapping of CD8
+
T cells.
31 In culture, hepatocytes promoted activa-
tion-induced cell death of T cells in an intercel-
lular adhesion molecule-1 (ICAM-1)-dependent
manner.
32 ICAM-1 is constitutively expressed in
hepatic sinusoids and was over-expressed in
hepatitis C-infected liver.
33,34 This suggests an
alternative model in which antigen presentation in
hepatocytes promotes T cell apoptosis and HCV
infection of the liver causes increased ICAM-1
expression, thereby promoting T cell apoptosis.
Our data are inconsistent with this latter model.
While abundant evidence links HCV core ex-
pression to T cell apoptosis, in our experimental
system in which HCV core expression was strictly
limited to hepatocytes, no effect of HCV core
protein on either apoptosis or activation of CD8
+
T cells was observed. We conclude that, while
HCV core protein might manipulate the T cell
response by acting in immune cells, it does not do
so in hepatocytes.
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